{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"This is the number of subjects that are laryngectomy-free at 12 months.","groups":[{"description":"Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin\n\nPembrolizumab: 200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses\n\nRadiation Therapy: 70 Gy in 35 fractions over 7 weeks\n\nCisplatin: 100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.","id":"OG000","title":"Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"12 months","title":"Laryngectomy-free Survival in Locally Advanced Laryngeal Squamous Cell Carcinoma","type":"SECONDARY","unitOfMeasure":"Participants"}